

PRESS RELEASE

17 APRIL 2026

NANOLOGICA AB (PUBL) RECEIVES ORDER OF APPX SEK 2 MILLION FROM CUSTOMER IN INDIA

Nanologica has received an order of appx. SEK 2 million for the company's silica-based purification media NLAB Saga®. The customer is a manufacturer of peptide drugs, and the order relates to evaluation of NLAB Saga® on a production scale.

Nanologica's team has been working with this customer for a few years, including carrying out an extensive application development project for them. With this order, the customer will proceed to evaluate NLAB Saga® on a production scale.

"After working with this customer for a long time, it is now very pleasing that we received this order which clearly shows that the customer is satisfied with our product quality and now wants to evaluate on a production scale to be able to include it in their manufacturing. It is also gratifying that this order relates to a particle size that is generally used by insulin manufacturers, which again indicates that we will be able to sell our different product types and not just the one that is generally used for purification of GLP-1 analogues. Our team has done a fantastic job with this customer and we look forward to continuing the work of streamlining our customers' workflows when it comes to purification of peptide-based drugs", comments Nanologica's CEO Andreas Bhagwani.

The order value amounts to appx. SEK 2 million at today's exchange rate and will be delivered immediately.

For further information, please contact:

Johanna Westerberg, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-17 07:57 CEST.

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The Group also includes Syntagon, a contract manufacturer of drug molecules for both clinical studies and commercial delivery. Syntagon works with chemical engineering manufacturing and the development of processes and analyses of pharmaceutical raw materials, with a core competence in small molecules and peptides, and a particular strength in purification and analysis of complex compounds. The Group is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

